482876d9-a6fb-4642-acbc-c3e45880e576
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.400
- MYC_TARGETS_V2+0.400
- WNT_BETA_CATENIN_SIGNALING+0.400
- DNA_REPAIR+0.300
- MYC_TARGETS_V1+0.300
- HEDGEHOG_SIGNALING+0.200
- MITOTIC_SPINDLE+0.200
- PANCREAS_BETA_CELLS+0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.200
Top 10 suppressed
- ANGIOGENESIS-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- IL6_JAK_STAT3_SIGNALING-0.400
- INFLAMMATORY_RESPONSE-0.400
- PROTEIN_SECRETION-0.400
- ALLOGRAFT_REJECTION-0.300
- ANDROGEN_RESPONSE-0.300
- COAGULATION-0.300
- COMPLEMENT-0.300
- INTERFERON_ALPHA_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-8580-01A-31R-2403-07 | — | cohortSQ2 | 0.888 |
| 2 | TCGA-56-7730-01A-11R-2125-07 | — | cohortSQ2 | 0.887 |
| 3 | TCGA-98-A53A-01A-11R-A262-07 | — | cohortSQ1 | 0.884 |
| 4 | TCGA-J1-A4AH-01A-31R-A24H-07 | — | cohortSQ2 | 0.875 |
| 5 | ERR2598250 | fetal | fetal | 0.871 |
| 6 | BS_8SKZ7BRN | low-grade glioma | — | 0.869 |
| 7 | ERR2598256 | fetal | fetal | 0.863 |
| 8 | BS_37GTVG4N | Embryonal tumors | — | 0.856 |
| 9 | BS_P39SQPTS | Embryonal tumors | — | 0.853 |
| 10 | 5d2d4263-d17d-424f-9c82-bf665306d71f | — | — | 0.851 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.400 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |